Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range374.00 - 3,900.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪21.46M
Enterprise Value7.56B
Total Cash (Recent Filing)₪8.54M
Total Debt (Recent Filing)₪71.00K
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Aug 27, 2026EPS Estimate
-49.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-Sheet FlexibilityVery low leverage materially reduces refinancing and interest-rate risk, giving management funding flexibility during multi-year clinical programs. This structural balance-sheet strength supports continued R&D investment and lowers near-term solvency risk versus highly leveraged peers.
High Gross Margin PotentialExtremely high gross margins indicate that if a candidate is commercialized, product-level economics could be attractive. Durable margin potential would support scalable profitability once revenue is established, improving long-term returns even if near-term losses persist during development.
Focused A3AR Platform And Diversified IndicationsA clear scientific focus on the A3AR pathway across inflammatory, liver, and oncology indications creates a durable platform advantage. Multiple clinical assets reduce single-product binary risk and preserve optionality, enabling value creation from different indications over an extended development horizon.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow have been materially negative each year, reflecting persistent cash burn. Even with reduced burn in 2025, the company lacks self-funding and will likely need recurrent financing, increasing dilution and funding-timing risk across the typical multi-year clinical cycle.
Shrinking Revenue And Widening LossesRevenue has been very small and is structurally declining while operating and net losses widened in 2025. The absence of growing commercial revenue means the company remains dependent on R&D milestones and external capital to reach sustainable sales, elevating long-term execution risk.
Negative ROE And Equity Volatility / Financing RiskSharp negative ROE and materially fluctuating equity reflect sustained dilution or losses and signal potential reliance on future capital raises. Structurally, this increases shareholder dilution risk and creates funding uncertainty that can impair long-term strategic flexibility and execution of trials.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 374.00 and its highest was 3900.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪21.46M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 46 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -898.755 earnings per share for the quarter, missing the consensus estimate of -21.076 by -877.679.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -49.68.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -898.755 in its last earnings report, missing expectations of -21.076. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.